Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

Elara sees the ongoing weakness as an opportunity to buy into the pharma space, as it expects robust earnings growth ahead at ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit these popular categories the hardest.

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Doximity reported strong Q3 performance, driven by high pharma client demand. Click here to find out why DOCS stock has been ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

Celltrion announced on Friday that it has received construction approval to build a new drug product (DP) manufacturing plant in Songdo, Incheon. The new facility, permitted by the Incheon Free ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Glenmark Pharmaceuticals (NSE: GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% ...